Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment

Bryan Oronsky, Neil Oronsky, Susan Knox

  • 1RadioRx, Inc, 800 W El Camino Real, Suite 180, Mountain View CA 94040. jscicinski@radiorx.com.

Insights

Epigenetic therapies like HDAC inhibitors and DNMTIs can potentially reverse chemotherapy resistance in metastatic cancer. These agents may reprogram tumors, offering new hope for resensitizing patients to previously ineffective treatments.

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • Acquired resistance to chemotherapy, biological, and targeted therapies is a significant clinical challenge in metastatic cancer.
  • This resistance was historically considered irreversible, limiting retreatment options.
  • Epigenetic therapies offer novel strategies to potentially overcome established drug resistance.

Purpose of the Study:

  • To explore mechanisms of small molecule agents in reprogramming tumors from a resistant to a non-resistant state.
  • To highlight recent findings on epigenetic reprogramming for overcoming cancer resistance.
  • To discuss the therapeutic potential of resensitization strategies with previously failed chemotherapies.

Main Methods:

  • Review of literature on epigenetic modifiers including HDAC inhibitors (entinostat, vorinostat) and DNA methyltransferase inhibitors (DNMTIs) like decitabine (DEC) and 5-azacytidine (5-AZA).
  • Exploration of redox modulators (RRx-001) in tumor reprogramming.
  • Analysis of recent findings and therapeutic potential for resensitization approaches.

Main Results:

  • Epigenetic agents may reverse non-genetic alterations contributing to chemoresistance.
  • Small molecules can potentially reconfigure tumors to a non-resistant state.
  • Resensitization approaches show promise for treating advanced metastatic cancer.

Conclusions:

  • Epigenetic therapies hold significant promise for overcoming acquired resistance in metastatic cancer.
  • Reprogramming tumors using agents like HDAC inhibitors, DNMTIs, and redox modulators can restore sensitivity to chemotherapy.
  • This approach offers a potential strategy for retreatment in patients with advanced disease.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.4K